Background
During recent years, coronary computed tomography angiography (CCTA) has emerged as an important non-invasive imaging modality for the assessment of coronary artery disease (CAD) . Multiple studies demonstrated a high diagnostic accuracy for the detection and the exclusion of coronary stenosis when compared with invasive coronary angiography and established CCTA as a useful alternative to invasive angiography in certain indications. Moreover, due to its ability to delineate non-obstructive plaques, both calcified and non-calcified, CCTA can detect early changes of CAD and, therefore, may serve as a new prognostic tool for assessing subsequent cardiac risk.
The prognostic value of CCTA for adverse cardiac events over short-to-intermediate follow-up has been shown in several singlecentre studies, 1 -5 a meta-analysis 6 as well as in a pooled analysis from multiple international centres 7 and follow-up of .25 000 CCTA-imaged patients is currently available. Nevertheless, the average follow-up duration of these studies is roughly 2 years, a time frame too short to adequately address atherosclerosis disease progression in view of the long latency between the onset of CAD and the occurrence of adverse clinical events. If CCTA is to prove useful for guiding preventive measures for CAD, longer follow-up periods are warranted.
As long-term surveillance data after CCTA imaging is very limited, we conducted extended follow-up of patients enrolled in a previously published CCTA study 8 and adjudicated outcomes out to 5 years.
The rationale of the study is to assess the long-term predictive value of CCTA for incident major cardiac events as well as to investigate the incremental predictive value and the risk reclassification utility in comparison with standard clinical risk assessment in a population of patients with suspected CAD.
Methods

Study population
We enrolled all consecutive patients undergoing CCTA at our institution from 1 December 2003 to 30 November 2006. Written informed consent was obtained from all the patients before the investigation.
Patients were eligible for this study, if CAD was not previously known, but suspected. Exclusion criteria comprised patients investigated in an acute life-threatening condition and patients without stable sinus rhythm during investigation. A structured interview was performed before the investigation, and information about age, height, and weight of the patient, symptoms, cardiac history, and current medication was collected. The following cardiac risk factors were recorded: (i) presence and degree of hypertension (for binary analysis hypertension was defined as a systolic blood pressure of .140 mmHg or the administration of antihypertensive therapy), (ii) diabetes mellitus (defined as fastening blood glucose level .7 mmol/L or use of oral anti-diabetic therapy or insulin), (iii) smoking (defined as current smoker or previous smoker within the last year) and (iv) a positive family history (defined as presence of CAD in first-degree relatives younger than 55 years in male or 65 years in female). In addition, laboratory tests for total cholesterol, LDL-and HDL-fraction, and triglycerides were performed. From these data, the Morise pre-test score and the CAD-consortium clinical risk for obstructive CAD were calculated. The Morise pre-test score extends the risk stratification by Diamond and Forrester 9 by including both risk factors and current symptoms and is the most recent clinical score validated for cardiac events. 10 Since this score fitted best to our patient population both regarding symptoms and endpoint, it was used to assess the pre-test cardiac risk. The CAD-consortium clinical risk prediction model estimates the presence of obstructive CAD based on clinical risk factors and symptoms.
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For the subgroup analysis according to symptoms, patients having both chest pain and dyspnoea were only assigned to the dyspnoea group if dyspnoea was the leading symptom. The study design was approved by the local ethics committee.
Computed tomography procedure
The detailed scan protocol is described elsewhere. In patients with a heart rate of .60 b.p.m., up to four doses of 5 mg of metoprolol were administered intravenously to lower heart rate at the beginning of the CT study. All the patients with a systolic blood pressure of at least 100 mmHg received nitroglycerin 0.8 mg sublingually for coronary vasodilatation after the patient was positioned on the scanner table. Images for calcium scoring were acquired by a non-contrast-enhanced sequential scan and analysed with a commercially available software package (Siemens Calcium Score, Siemens, Erlangen, Germany) using the Agatston score with a threshold of 130 HU. Contrast timing was tested by an initial bolus-timing scan using 10-20 ml of contrast (Iomeprol, Imeron 350, Bracco Altana Pharma GmbH, Konstanz, Germany, iodine content 350 mg/ml) followed by a 50 ml saline chaser. The contrast-enhanced scan was obtained using 80-140 ml of contrast individually adapted to the selected table feed and scan range at a rate of 4-6 ml/s followed by a 50 ml saline chaser. Data sets of axial slices, multiplanar reformations, and three perpendicular sets of thin-slab maximum intensity projections orientated along the heart axis (5 mm thickness, 1 mm increment) were reconstructed and investigated for the presence of plaque composition and luminal stenosis.
The coronary artery tree was segmented according to a simplified American Heart Association classification 14 using only the first 15 segments of the original 18. Each vessel segment with a diameter .1.5 mm was evaluated visually by two readers with an experience of having read .400 cardiac CT-studies at the time the scan was read.
Any disagreement was settled by consensus. The results are based on clinical reads. The degree of stenosis was rated visually using four groups: no relevant stenosis (,25%), mild (25 -49%), moderate (50 -74%), and severe (≥75%) stenosis. Segments with artefacts were assigned to the most appropriate group. In addition, for each segment the presence of calcified and noncalcified plaques were assessed. Calcified plaques were defined as plaques in the coronary wall showing signal intensities well above the contrast of the vessel lumen. Non-calcified plaques were defined as any noncalcified stenosis .25% or any discernible structure in the coronary artery wall with a CT density less than the contrast-enhanced coronary lumen but greater than the surrounding connective tissue. Plaques meeting these criteria, but additionally showing calcification, were classified as mixed plaques. From the primary analysis the following CCTA scores were calculated:
CAD severity as proposed by Chow et al. 5 with the categories 'normal', 'non-obstructive', 'one-vessel obstructive', 'two-vessel obstructive' and 'three-vessel obstructive'. Total plaque score: number of segments with any stenosis ≥25% or any calcified, mixed or non-calcified plaques, irrespective of the degree of stenosis. 1, 5 In addition the non-calcified, mixed, and calcified plaque score, defined as the number of coronary segments with non-calcified, mixed or calcified plaques irrespective of stenosis was calculated. Derived scores : for comparison, two recently published scores were calculated: The segment stenosis score combining number and degree of stenoses and the modified Duke score combining number, degree and proximal location of stenoses, both proposed by Min et al. 
Follow-up
Follow-up information was obtained by clinical visits if available (10%), by detailed questionnaires sent by mail (40%), or, if the questionnaire was not returned, by telephone contact (50%, all numbers estimated based on a representative subsample of 261 patients scanned in 6 randomly selected months). All reported events were verified by hospital records or direct contacts with the attending physician as possible and adjudicated by two cardiologists in consensus.
The primary endpoint of this study was a composite endpoint including death of any cause and non-fatal myocardial infarction. Non-fatal myocardial infarction was defined based on the criteria of typical acute chest pain and persistent ST-segment elevation or positive cardiac enzymes.
Two secondary endpoints were defined: first, cardiac events, defined as a composite of cardiac death and myocardial infarction (with cardiac death defined as any death of clearly cardiac cause and any death of unknown reason), and second, the single endpoint of late revascularization defined as percutaneous coronary intervention or bypass surgery performed later than 90 days after CCTA. Coronary revascularizations within 90 days after CCTA were not counted as events, because they most likely were performed in the context of an invasive angiography that was recommended due to abnormal CCTA findings; to eliminate confounding from restenosis, these patients were censored at the time of the first revascularization.
This study re-analyses patients from a previous study 8 extending the follow-up period from 2.4 to 5.5 years. Follow-up events were defined prospectively; but the performance of this analysis and its point in time was not prospectively specified.
Statistical analysis
Categorical Data are given as means + standard deviation (median and inter-quartile range for CAD-Consortium risk because of marked non-normal distribution) or absolute numbers and percentages, since only one indication is counted for each patient there may be differences to the number of symptoms. including the package rms, 18 was used for statistical analysis.
Results
Study population and clinical characteristics
During the study period 1714 patients with suspected CAD underwent CCTA. In total 94 patients were excluded per protocol, seven patients with acute aortic dissection undergoing pre-operative assessment for CAD, 2 patients because of other life-threatening conditions and 85 patients due to the absence of stable sinus rhythm during the examination. Of the 1620 remaining patients, 1584 (97.8%) were contacted for follow-up at a median of 5.5 years (inter-quartile range 5.1-6.2 years). The mean patient age was 58 + 11 years and 1091 patients (69%) were male. The pre-test risk assessed by the Morise score was low in 348 patients (22%), intermediate in 1122 patients (71%), and high in 141 patients (7%). In sensitivity analyses, except for a higher body mass index in patients lost on follow-up, there was no significant difference between the overall study population and the population lost on follow-up. Detailed patient baseline characteristics are provided in Table 1 .
Computed tomography results
The CT scan was performed on a 16-slice scanner in 305 patients (19%), on a 64-slice single source scanner in 1168 patients (74%), and on a 64-slice dual source scanner in 111 patients (7% Calcium scoring was performed in 1483 patients (94%). The median Agatston score was 93 (IQR 0 -1252). A summary of the CT results is shown in Table 2 .
Follow-up events
During follow-up, the primary endpoint of death or non-fatal myocardial infarction occurred in 61 patients (3.8%). Overall 48 patients (3.0%) died; 12 patients (0.8%) from cardiac causes and 36 patients (2.3%) from non-cardiac causes. In addition 13 patients (0.8%) suffered from non-fatal myocardial infarction. Overall, the annual rate of death or myocardial infarction was 0.7% (95% CI: 0.6 -0.9%).
The secondary endpoint of cardiac events occurred in 25 patients (1.6%). During the follow-up 226 patients (14%) underwent coronary revascularization, of which 174 (11%) were performed within 90 days after CCTA and 52 (3.3%) beyond 90 days. There were 48 late percutaneous coronary interventions (3.0%) and 7 late bypass graft surgeries (0.3%), 3 patients had both types of intervention.
Prognostic value of coronary computed tomography angiography
For the primary endpoint, both CAD severity and total plaque score correlated well with outcome. Coronary artery disease severity had a univariate c-index of 0.63 and a multivariate c-index of 0.59. The total plaque score performed slightly better with a univariate and multivariate c-index of 0.70 and 0.66, respectively. The annual event rate for the primary endpoint ranged from 0.2% (95% CI: 0.1 -0.5%) for patients without CAD to 0.81% (95% CI: 0.58-1.1%) for patients with non-obstructive CAD to 1.1% (95% CI: 0.7 -1.8%) for patients with obstructive CAD; patients with a total plaque score of more than five segments had an annual event rate of 1.5% (95% CI: 1.1 -2.2%). Of note is the fact that total plaque score counting segments with any plaque or stenosis performed better than a score counting segments with mild (.25%) obstruction (multivariate c-index 0.63) and a score counting segments with moderate (.50%) obstruction (multivariate c-index 0.56). Plaque classification did not improve prediction, non-calcified, mixed, and calcified plaques scores all had multivariate c-indices between 0.58 and 0.59 at the border of significance. Further details of the prognostic value of CCTA are summarized in Table 3 and Figure 1 . Prognostic assessment was similar between 16-slice scanners and later generations with a trend for correlation between CAD severity and primary endpoint (multivariate c-index 0.60, P ¼ 0.14 and c-index ¼ 0.57, P ¼ 0.11, respectively) and a significant correlation between total plaque score and outcome (multivariate c-index 0.81, P , 0.001 and c-index ¼ 0.60, P ¼ 0.028, respectively).
For the secondary endpoint of cardiac events, the correlation between CCTA variables and outcome was slightly better. The multivariate c-indices of the total plaque score and the CAD severity score were 0.74 (P , 0.0001) and 0.68 (P ¼ 0.0012), respectively (see also Table 4 ).
For the secondary endpoint of late revascularization, CAD severity performed best [hazard ratio of 1.7 (95% CI: 1.3 -2.2), c-index 0.659, P , 0.0001]. The total plaque score performed slightly worse with a hazard ratio of 1.9 (95% CI: 1.3 -2.7) and a c-index of 0.636 (P ¼ 0.0013, all multivariate). Kaplan-Meier curves are shown in Figure 2 .
Subgroup analysis according to symptoms
For the primary endpoint, annual event rate was highest in patients with dyspnoea (1.3%, 95% CI: 0.56-2.8%) and lower for patients with chest pain (0.77%, 95% CI: 0.53 -1.1%) and other or no symptoms (0.60%, 95% CI: 0.42-0.87%). None of these differences was significant.
Correlation between CCTA parameters and outcome was similar between patients with chest pain and those no or other symptoms. For the total plaque score c-index was 0.64 (P ¼ 0.0015) for patients with chest pain and 0.66 (P ¼ 0.0051) for those without chest pain and dyspnoea. In the few patients with dyspnoea, no correlation was significant (see also Table 5 ).
Comparison with calcium scoring
Calcium scoring significantly improved prediction beyond the Morise score both for the primary endpoint and the cardiac events. The c-index rose from 0.661 to 0.703 (P ¼ 0.034) and from 0.636 to 0.713 (P ¼ 0.034), respectively. For the primary endpoint no CCTA variable could further improve prediction (c-index for the total plaque score 0.718, P not significant), while for cardiac events the combination of the Morise score, calcium score, and total plaque score had a better predictive value than the Morise and calcium score alone (c-index ¼ 0.745, P ¼ 0.034 for difference) (Figure 3) . Figure 1 Kaplan-Meier plot for event-free survival stratified for total plaque score (upper plot) and coronary artery disease severity (lower plot).
Prognostic value of coronary CT-angiography
Reclassification from clinical risk
A substantial number of patients could be reclassified regarding their risk after performance of CCTA. The total plaque score showed an overall net reclassification improvement of 49% (P ¼ 0.0002) for the primary endpoint and 54% (P ¼ 0.0028) for cardiac events. While all variables showed a highly significant improvement in identifying patients without events (all P , 0.0001), no parameter could significantly improve prediction of events (all P . 0.32) ( Table 6 and Figure 4 ).
Discussion
For patients with suspected CAD, we could demonstrate that (i) the exclusion of CAD by CCTA is associated with an excellent prognosis over the subsequent five years with an annual rate of major events well ,0.5%; (ii) both the severity of CAD and the total plaque score can be used to identify patients at high long-term risk deserving intensified medical therapy; and (iii) about half of all the patients can be reclassified regarding their 5-year cardiac risk.
Coronary obstruction is the hallmark of advanced CAD and although the obstruction itself may be alleviated by revascularization, these patients remain at increased risk. In our study, the conventional classification of CAD severity correlated well with outcome. However, additional analyses including the total plaque score, which also takes into account non-obstructive plaques, carried additional prognostic information. Indeed in our study the total plaque score is one of the best . ............ ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ .... predictors of outcome, surpassing scores that only count segments with mild or moderate obstruction. While these findings already were observed at 2-year follow-up, 8 this study confirms that the prognostic power of CCTA endures over a 5-year period, a time-frame which much better reflects the natural history of evolving CAD and the impact of targeted therapeutic strategies.
The results of our analysis are consistent with other emerging data on long-term follow-up after CCTA imaging. In a small study, Chong et al. 19 observed 70 patients without obstructive CAD out of a cohort of 259 patients for the occurrence of major cardiac events during a mean follow-up of 4.6 years, and observed just a single myocardial infarction event, concluding that the negative predictive value of a CCTA without evidence of CAD for long-term major cardiac events is 99% (95% CI: 92-99%). Andreini et al. 20 analysed 980 patients with suspected CAD for hard cardiac events (cardiac death or myocardial infarction) and major cardiac events (additionally including late revascularizations) during a follow-up period of 4.3 years. They found a significant improvement of event prediction beyond clinical risk scores both for obstructive CAD and the number of segments with plaque. Annual rates of major cardiac events ranged from 0% for patients without CAD to 19.9% for patients with obstructive CAD. The main limitation of this study was the fact that 22% of the original population was excluded because of inconclusive CCTA findings or early coronary revascularization. Similar results were found by Ostrom et al. 21 who assessed the mortality incidence after electron-beam CCTA during a 6.5-year follow-up and describe annual mortality rates between 0.25% for patients without CAD to 1.3% for those with evidence of obstructive CAD.
Hard clinical endpoints, like mortality or myocardial infarction, are of cause the most important parameters for assessing the prognostic value of CCTA. But the risk of other CAD-associated morbidity such as the presence of symptomatic angina pectoris and/or need for subsequent revascularization may influence decisions on the intensity of preventive measures. Our data confirms that CCTA can also predict need for subsequent coronary revascularization and while the correlation between the presence of obstructive CAD and subsequent revascularization is not surprising, the correlation between the total plaque score and the revascularization rate is not self-evident. While this result in part is caused by a moderate correlation between plaque load and coronary obstruction, it may also reflect the higher risk of plaque progression in patients with extensive disease ultimately leading to a higher incidence of obstructive lesions.
For the total plaque score, we found a slight but significant improvement in cardiac event prediction compared with a combined model of Calcium scoring and Morise score. Taking into account the observation by Cho et al.,
22 who could not demonstrate an incremental predictive value of CCTA in 7590 asymptomatic individuals, and the non-significant result for prediction of the primary endpoint in our analysis, further evaluation of the use of this parameter for the assessment of cardiac risk is warranted, a task beyond the scope of this study. An additional analysis looking at the reclassification of patient risk from pre-test clinical risk scores indicated that 49% of the patients could be reclassified regarding their cardiac risk. In particular, the prediction of an event-free follow-up could be improved by all the CCTA variables analysed. Nevertheless, patients with a high pre-test risk and a low risk CCTA had an annual event rate as high as 1%. Although there is an uncertainty in this number due to the small subgroup, the incremental prognostic value of CCTA in high-risk patients may be limited.
The results from this study further support the role of CCTA as an additional means of assessing cardiovascular risk. 
Limitations
This is an observational single-centre study. The results may be affected by characteristics unique to the patients investigated. Furthermore, outcome might be confounded by treatment decisions based on the results of the investigation. In addition, complete information on medication prescription and compliance during the follow-up is not available. More than 30 patients were lost on follow-up; events in these patients could significantly alter the findings of this study.
Compared with other studies the study population has a higher number of patients without chest pain and ischaemia and a lower rate of obstructive CAD. In addition, the event rate, particularly for cardiac death and myocardial infarction is quite low. Although we found no difference in the predictive value of CCTA between patient with and without chest pain, the results of this study may not be generalizable to other populations.
The results of our study should be validated by a multicentre analysis.
Conclusion
In a large population of .1500 patients with suspected CAD, CCTA proved a useful tool in predicting cardiovascular outcomes over long-term follow-up out to 5 years. While the exclusion of atherosclerotic changes in CCTA is associated with an excellent prognosis, the documentation of both atherosclerotic plaques (CAD without obstruction) and of obstructive CAD in CCTA improve the risk prediction for hard cardiovascular endpoints including death and myocardial infarction over and above the predictive ability of traditional clinical risk scores. In addition, both parameters predicted the risk of need for subsequent coronary revascularization. The results of our analysis should be confirmed by larger multicentre studies.
